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Abstract
Objective: In this study, 22 cases of locally recurrent uro-
logical malignant fibrous histiocytoma were reviewed
considering therapeutic options, follow-up and progno-
sis. Patients and Methods: In the available literature on
this topic we identified 19 cases of locally recurrent geni-
tourinary malignant fibrous histiocytoma. Three addi-
tional cases are discussed, primarily arising from the kid-
ney, the bladder and the paratesticular region. Results:
The prognosis of locally recurrent urological malignant
fibrous histiocytoma was found to be extraordinarily
poor. Only 2 of 22 patients have survived for longer than
3.5 years. One of them reported herein is still alive 10
years after extensive lymphatic spread accompanying
the first local recurrence. In this case, late local recur-
rence occurred after an 8-year interval free of disease.
Conclusion: Malignant fibrous histiocytoma is an unusu-
al urological malignancy with a high rate of local recur-
rence. The latter is frequently accompanied by metastat-
ic disease and unrelenting progression. Despite the poor
prognosis early detection of local failure and aggressive
salvage therapy might offer the chance of long-term sur-
vival in selected cases. Close and life-long follow-up is
advisable for patients once treated for recurrent urologi-
cal malignant fibrous histiocytoma.
Introduction
Malignant fibrous histiocytoma comprises a potpourri
of poorly differentiated sarcomas with similar pathohisto-
logical, biological and clinical characteristics [1, 2]. Pri-
mary involvement of the genitourinary tract is rare with
about 100 previously reported cases. Although local recur-
rence is common, a review of the literature yielded only
19 urological cases (table 1). We report on 3 additional
cases with local recurrence after surgical treatment includ-
ing 1 case with a remarkable 11-year survival after meta-
static disease.
Raghavaiah et al. [20] 1980
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Case Reports
Case 1
A 72-year-old man was admitted to the hospital with fever of
unknown origin, a highly accelerated erythrocyte sedimentation rate,
general weakness and left flank pain. Abdominal computed tomogra-
phy disclosed a 10 ! 15 cm left renal mass. Left radical nephrectomy
was performed through a transperitoneal approach. Histopatholog-
ical examination revealed a cellular neoplasm consisting of elon-
gated, partially fusiform cells forming fascicles and occasionally dis-
playing a storiform pattern. Extensive necrosis was present. More
than 20 mitoses were observed in 10 high power fields. Between the
tumor cells there was a dense lymphocellular infiltration. Immuno-
histological staining was positive for vimentin and ·1-antitrypsin and
negative for cytokeratin, desmin, actin and an epithelial marker. The
histopathological diagnosis was inflammatory malignant fibrous his-
tiocytoma. Cytokines secreted by this subtype are probably responsi-
ble for the paraneoplastic symptoms mentioned [2]. The tumor had
used up the major part of the kidney and was covered by the fibrous
renal capsule. There was no invasion beyond this structure. With
these findings, it was not possible to define the origin (primary renal
versus renal capsular) with certainty. The renal pelvis, major blood
vessels and a biopsy of the tumor bed were free of tumor. Local recur-
rences were resected after intervals of 12, 24, 40, 60 and 66 months.
Between the operations the patient enjoyed a good quality of life. He
died of a further widespread abdominal recurrence 72 months after
initial nephrectomy.
Case 2
A 55-year-old man underwent transurethral resection and radical
cystoprostatectomy with construction of an ileal conduit for a high-
grade pleomorphic malignant fibrous histiocytoma of the bladder
(fig. 1a). Microscopically, the tumor consisted of highly pleomorphic
mostly polygonal cells occasionally arranged in fascicles and whirls.
Bizarre Touton’s giant cells were present. Immunohistochemical
staining was negative for epithelial markers and positive for the his-
tiocyte markers Ki-M1p and CD-68. The extensively necrotic tumor
invaded the perivesical tissue, but the surgical margins and a biopsy
of the tumor bed were free of disease. Left ureteral obstruction
occurred 5 months postoperatively. Local recurrence was confirmed
by CT scan and transrectal biopsy (fig. 1b, 2). The lesion was consid-
ered to be inoperable. Palliative surgery (nephrostomy, colostomy)
was performed, and the patient died of tumor progression 7 months
later.
Case 3
A 68-year-old man had a left orchiectomy for a paratesticular
tumor at a different hospital. The histopathological diagnosis was
Table 1. Treatment and outcome of locally recurrent urological malignant fibrous histiocytoma: literature review
Authors, year Origin Subtype Initial
treatment
Time until
first local
recurrence
Distant failure Treatment
of local
recurrence
Follow-up after
first local
recurrence
Kidney Storiform-pleom. S 9.5 months Lung None 0 months (DOD)
Singh et al. [21] 1982 Kidney NA S 3 months None None 2 months (DOD)
Igarashi et al. [22] 1982 Kidney Storiform-pleom. S 18 months None S NA
Adolphs et al. [23] 1982 Kidney NA S 22 months None RT, XRT 10 months (dead1)
Srinivas et al. [24] 1984 Kidney Storiform-pleom. S 24 months None RT 10 months (DOD)
Scriven et al. [25] 1984 Kidney Storiform-pleom. S, XRT 4 months Widespread None 6 months (DOD)
Hansen et al. [26] 1989 Kidney Storiform-pleom. S 8 months Widespread NA NA
Grignon et al. [27] 1990 Kidney Storiform-pleom. S, CH, XRT NA NA RT NA (DOD2)
Inoue et al. [28] 1990 Kidney Storiform-pleom. S 9 months None None 5 months (DOD)
Present case 1 Kidney Inflammatory S 12 months None S 60 months (DOD)
Goodman and Greaney [29] 1985 Bladder Storiform-pleom. S 5 months Peritoneal S (palliative) NA (DOD)
McCormick et al. [30] 1985 Bladder Storiform-pleom. S 3 months Lung None 4 months (DOD)
Egawa et al. [31] 1994 Bladder Storiform-pleom. S 4 months None RT 7 months (DOD)
Barriol et al. [32] 1997 Bladder Storiform-pleom. S 2 months None None 0 months (dead3)
Present case 2 Bladder Storiform-pleom. S 5 months None S (palliative) 7 months (DOD)
Kumala et al. [33] 1994 Prostate Storiform-pleom. S, XRT 3.5 years Lung CH 2.5 years (AWD)
Cole et al. [34] 1972 Paratesticular Storiform-pleom. S 12 months [14] Lung, lymphatic None 3.5 years (DOD) [5]
Williamson et al. [35] 1980 Paratesticular Storiform-pleom. S 18 months Lymphatic S, CH, XRT NA
Adolphs et al. [23] 1982 Paratesticular NA S 3 years None S 9 months (DOD)
Paratesticular NA S, XRT 18 months Lung S, CH, XRT NA (DOD)
Tanaka et al. [36] 1984 Paratesticular Storiform-pleom. S 1 year None None 2 years (AWD)
Present case 3 Paratesticular Myxoid S 20 months Lymphatic S, XRT 133 months (NED)
pleom. = Pleomorphic; DOD = dead of disease; AWD = alive with disease; NED = no evidence of disease; NA = not available;
S = surgery; CH = chemotherapy; XRT = radiotherapy.
1 Died due to insufficiency of enteric anastomosis after extensive tumor resection.
2 Died 10 months after nephrectomy.
3 Dialysis discontinued.
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Fig. 1. Pleomorphic malignant fibrous histiocytoma of the anterior
wall of the bladder (a) and local recurrence occupying the prostate
bed (b, arrows), axial CT scans (case 2).
Fig. 2. Locally recurrent pleomorphic malignant fibrous histiocyto-
ma in the prostate bed, transversal endorectal 7.5-MHz ultrasound
(case 2).
‘plexiform neurofibroma with myxoid change of the stroma’. How-
ever, later reevaluation of the slides confirmed myxoid malignant
fibrous histiocytoma removed with positive surgical margins. The
tumor recurred locally accompanied by extensive lymphographically
proven inguinal, iliac and para-aortal lymph node involvement 20
months later (fig. 3a,b). A left hemiscrotectomy was performed. His-
topathology revealed a cellular neoplasm with myxoid stroma. The
fusiform cells formed fascicles and whirls. The nuclei were moderate-
ly polymorphic. Uni- and multinucleated giant cells were present.
The histopathologic diagnosis was recurrent myxoid malignant fi-
brous histiocytoma. Subsequently, the patient received a course of
4.680 cGy to the para-aortal region and of 5.040 cGy to the ilial and
inguinal nodes resulting in complete remission. Two more local
relapses were surgically removed 15 and 24 months later. After a 96-
month period free of disease, a contralateral paratesticular recur-
rence 6 cm in diameter was found (fig. 4) and treated by right radical
orchiectomy and complete scrotectomy. Recurrent myxoid malig-
nant fibrous histiocytoma with scattered storiform pattern was seen
microscopically (fig. 5a,b). Thirteen months later the patient was well
and without evidence of recurrent disease.
1b
2
1a
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Fig. 3. Extensive bilateral lymphatic spread of a locally recurrent
left-sided paratesticular myoxoid malignant fibrous histiocytoma (a)
partially showing a characteristic calciform pattern of contrast me-
dium storage (b, arrow), bipedal lymphography (case 3).
Fig. 4. Echoinhomogeneous neoplastic lesion (arrows) caudolateral
to the right testicle (right), 120 months after diagnosis of lymph node
failure, 7.5-MHz ultrasound (case 3).
3b
4
3a
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Fig. 5. Microscopic appearance of the tumor shown in figure 4 (case 3, a, original magnification !200), compared
with the last local recurrence 8 years ago (b, original magnification !200).
Discussion
Beside liposarcoma, malignant fibrous histiocytoma is
one of the two most common soft tissue sarcomas in
adults. The limbs, the trunk and the retroperitoneal space
are predilective sites [2–7]. The histological appearance is
characterized by four subtypes [2]: myxoid, storiform-
pleomorphic, inflammatory, and giant cell. Myxoid ma-
lignant fibrous histiocytoma shares the local but not dis-
tant aggressiveness of the other subtypes [1, 2, 4]. For this
reason, Enzinger and Weiss [2] classified myxoid sybtype
as grade II in contrast to the majority of malignant fibrous
histiocytoma which were classified as grade III. Current
grading systems classify sarcomas based on three criteria:
tumor differentiation, mitosis count, and necrosis [8].
The grading is obtained by summarizing the scores for
each single parameter to a final score [8].
In large studies local recurrence occurred in up to 51%
after apparently complete surgical removal of malignant
fibrous histiocytoma [6, 7]. The retroperitoneum is an
adverse site of origin with a 5-year survival rate of only
14% probably due to late diagnosis and difficult surgical
accessibility [1, 6, 9, 10]. Local recurrence may be accom-
panied by an increased malignant potential and is consid-
ered to be a risk marker for distant failure [4, 11, 12].
Cases 1 and 2 shared almost all the adverse prognostic cri-
teria recently established in a multicenter series of 216
patients [1]: age older than 50 years; tumor size 18 cm,
and a deeply invading high-grade nonmyxoid tumor. In
case 2, it was probably anatomically impossible to obtain
ba
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a sufficiently wide resection due to the perivesical infiltra-
tion by this highly aggressive sarcoma known for its abili-
ty to spread along fascial planes [2] and the location deep
inside the male true pelvis. In contrast to this rapidly fatal
course, case 1 illustrates that an aggressive surgical rein-
tervention might be beneficial in selected cases.
Although lymphatic spread is more common in para-
testicular sarcoma than in sarcomas of other origin [2, 6,
13, 14], the prognosis is more favorable certainly because
of earlier detection [1, 5]. Case 3 is unique considering the
long-term survival after the occurrence of extensive
lymph node metastases. To our knowledge this is the first
case of survival for longer than 10 years after metastatic
genitourinary malignant fibrous histiocytoma reported in
the available literature. Furthermore, the late local recur-
rence 8 years after the last tumor resection is remarkable.
This case history reflects the lower malignant potential of
the myxoid subtype. The favorable course in case 3 is an
argument for lymph node irradiation either adjuvantly or
after the occurrence of nodal failure, but little data are
available [3]. The efficacy of retroperitoneal lymph node
dissection or chemotherapy is limited in paratesticular
malignant fibrous histiocytoma [4, 5, 9, 13–17]. In myx-
oid malignant fibrous histiocytoma, doxorubicin- and da-
carbazine-based chemotherapy has a modest activity [18].
Recently, a meta-analysis of 14 randomized sarcoma
trials demonstrated a significant advantage for adjuvant
doxorubicin-based chemotherapy for local, distant and
overall disease control and a trend towards prolonged
overall survival [19]. However, the putative advantage is
small and there is considerable toxicity [19]. Further
research is needed to establish an active adjuvant chemo-
therapy protocol in malignant fibrous histiocytoma. Wide
resection followed, if possible, by adjuvant radiotherapy
is the only potentially curative treatment for primary or
locally recurrent malignant fibrous histiocytoma [1, 3, 4,
9, 15]. A review of the literature demonstrates the dismal
prognosis of locally recurrent urological malignant fibrous
histiocytoma (table 1). Local relapse is often accompanied
by distant failure, and there is no promising therapy for
systemic disease. The vast majority of the recurrences
arose within 3 years after surgery (table 1). However, after
adjuvant radiotherapy for retroperitoneal sarcomas later
recurrences were observed [16]. The 2 reported cases with
5- and more than 11-year survivals despite locally recur-
rent and (in case 3) even metastatic disease indicate that
individual patients might benefit from aggressive salvage
therapy. Nevertheless, definitive eradication of the tumor
is very unlikely (table 1). Therefore patients once treated
for locally recurrent urological malignant fibrous histiocy-
toma should have close and life-long follow-up.
In conclusion, malignant fibrous histiocytoma rarely
arises in the genitourinary tract and possesses a high ten-
dency towards local recurrence. The latter is frequently
accompanied by metastatic spread and unrelenting pro-
gression. Despite the poor prognosis a prediction of the
individual biological behavior of the locally recurrent
tumor is difficult. Early detection of local failure and
aggressive salvage therapy might enable long-term surviv-
al in selected cases.
Acknowledgement
The authors wish to thank Prof. J. Justus, head of the Department
of Pathology, Dresden-Friedrichstadt Hospital, for kindly reviewing
the slides of the primary tumor in case 3.
References
1 Le Doussal V, Coindre JM, Leroux A, Hacene
K, Terrier P, N’guyen BB, Bonichon F, Collin
F, Mandard AM, Contesso G: Prognostic fac-
tors for patients with localized primary malig-
nant fibrous histiocytoma. Cancer 1996;77:
823–830.
2 Enzinger FM, Weiss SW: Malignant fibrohis-
tiocytotic tumors; in Enzinger FM, Weiss SW
(eds): Soft Tissue Tumors, ed 3. St Louis, Mos-
by 1995, pp 351–379.
3 Fagundes HM, Lai PP, Dehner LP, Perez CA,
Garcia DM, Emami BN, Simpson JR, Kraybill
WG, Kucick NA: Postoperative radiotherapy
for malignant fibrous histiocytoma. Int J Ra-
diat Oncol Biol Phys 1992;23:615–619.
4 Zagars GK, Mullen JR, Pollack A: Malignant
fibrous histiocytoma: outcome and prognostic
factors following conservation surgery and ra-
diotherapy. Int J Radiat Oncol Biol Phys 1996;
34:983–994.
5 Glazier DB, Vates TS, Cummings KB, Pickens
RL: Malignant fibrous histiocytoma of the
spermatic cord. J Urol 1996;155:955–957.
6 Kearney MM, Soule EH, Ivins JC: Malignant
fibrous histiocytoma. A retrospective study of
167 cases. Cancer 1980;45:167–178.
7 Weiss SW, Enzinger FM: Malignant fibrous
histiocytoma: An analysis of 200 cases. Cancer
1978;41:2250–2266.
8 Guillou L, Coindre JM, Bonichon F, Bui NB,
Terrier P, Collin F, Vilain MO, Mandard AM,
LeDoussal V, Lerous A, Jacquemier J, Duplay
H, Satre-Garau X, Costa J: Comparative study
of the National Cancer Institute and French
Federation of Cancer Centers Sarcoma Group
grading systems in a population of 410 adult
patients with soft tissue sarcoma. J Clin Oncol
1997;15:350–362.
9 Tepper JE, Suit HD, Wood WC, Proppe KH,
Harmon D, McNulty P: Radiation therapy of
retroperitoneal soft tissue sarcoma. Int J Ra-
diat Oncol Biol Phys 1984;10:825–830.
170 Urol Int 1999;62:164–170 Froehner/Manseck/Haase/Hakenberg/
Wirth
10 Zornig C, Weh HJ, Krull A, Schwarz R, Dieck-
man J, Rehpenning W, Schroder S: Retroperi-
toneal sarcoma in a series of 51 adults. Eur J
Surg Oncol 1992;18:475–480.
11 Kuratsu S, Ohsawa M, Naka N, Myoui A,
Tomita Y, Uchida A, Ono K, Aozasa K: Use-
fulness of argyrophilic nucleolar organizer
staining for predicting prognosis of patients
with recurrent soft tissue sarcoma. Oncology
1994;51:244–250.
12 Gustafson P: Soft tissue sarcoma. Epidemiolo-
gy and prognosis in 508 patients. Acta Orthop
Scand 1994;259(suppl):1–31.
13 Fagundes MA, Ziethman AL, Althausen AF,
Coen JJ, Shipley WU: The management of
spermatic cord sarcoma. Cancer 1996;77:
1873–1876.
14 Sclama AO, Berger BW, Sherry JM, Young JD:
Malignant fibrous histiocytoma of the spermat-
ic cord: The role of retroperitoneal lymphaden-
ectomy in management. J Urol 1983;130:577–
579.
15 Oesterling JE, Epstein JI, Brendler CB: Myxoid
malignant fibrous histiocytoma of the bladder.
Cancer 1990;66:1836–1842.
16 Catton CN, O’Sullivan B, Kotwall C, Cum-
mings B, Hao Y, Fornasier V: Outcome and
prognosis of retroperitoneal soft tissue sarco-
ma. Int J Radiat Oncol Biol Phys 1994;29:
1005–1010.
17 Casper ES, Gainor JJ, Harrison LB, Panicek
DM, Haidu SI, Brennan MF: Preoperative and
postoperative adjuvant combination chemo-
therapy for adults with high grade soft tissue
sarcoma. Cancer 1994;73:1644–1651.
18 Patel SR, Plager C, Papadopoulos NE, Benja-
min RS: Myxoid malignant fibrous histiocyto-
ma: Experience with chemotherapy. Am J Clin
Oncol 1995;18:528–531.
19 Sarcoma Meta-Analysis Collaboration: Adju-
vant chemotherapy for localised resectable
soft-tissue sarcoma of adults: Meta-analysis of
individual data. Lancet 1997;350:1647–1654.
20 Raghavaiah NV, Mayer RF, Hagitt R, Soloway
MS: Malignant fibrous histiocytoma of the kid-
ney. J Urol 1980;123:951–953.
21 Singh EO, Barrett DM, Adams VI: Synchro-
nous occurring malignant fibrous histiocytoma
of the kidney with contralateral renal cell carci-
noma. J Urol 1982;128:586–588.
22 Igarashi J, Asoka H, Nogaki J, Morita H,
Okada K, Kishimoto T: Malignant fibrous his-
tiocytoma of the renal fibrous capsule. Jpn J
Clin Oncol 1982;36:1141–1144.
23 Adolphs HD, Helpap B, Koischwitz D: Retro-
peritoneal and inguinal manifestation of malig-
nant fibrous histiocytoma. Urology 1982;20:
1639–1645.
24 Srinivas V, Sogani PC, Hajdu SI, Whitmore
WF: Sarcomas of the kidney. J Urol 1984;132:
13–16.
25 Scriven RR, Thrasher TV, Smith DC, Steward
SC: Primary renal malignant fibrous histiocy-
toma: A case report and literature review. J
Urol 1984;131:948–949.
26 Hansen CP, Meinert Jensen L, Holten I: Malig-
nant fibrous histiocytoma of the kidney. Eur
Urol 1989;16:395–397.
27 Grignon DJ, Ayala AG, Ro JY, el-Naggar A,
Papadopoulos NJ: Primary sarcomas of the
kidney. A clinicopathologic and DNA flow cy-
tometric study of 17 cases. Cancer 1990;65:
1611–1618.
28 Inoue H, Okada S, Hongo Y, Kirime S, Ohara
H, Takasaki N: Malignant fibrous histiocyto-
ma arising from the renal capsule: Report of a
case. Acta Urol Jpn 1990;36:45–50.
29 Goodman AJ, Greaney MG: Malignant fibrous
histiocytoma of the bladder. Br J Urol 1985;57:
106–107.
30 McCormick SR, Dodds PR, Kraus PA, Lowell
DM: Nonepithelial neoplasma arising within
vesical diverticula. Urology 1985;25:405–408.
31 Egawa S, Uchida T, Koshiba K, Kagata Y, Iwa-
buchi K: Malignant fibrous histiocytoma of the
bladder with focal rhabdoid tumor differentia-
tion. J Urol 1994;151:154–156.
32 Barriol D, Lechevallier E, Ortega JC, Koutani
A, Dussol B, de Fromont M, Coulange C: His-
tiocytofibrome malin de la vessie. A propos
d’un cas. Prog Urol 1997;7:270–272.
33 Kumala RV, Sappänen JH, Vaajalahti PJ,
Tammela TLJ: Malignant fibrous histiocytoma
of the prostate. Scand J Urol Nephrol 1994;28:
429–431.
34 Cole AT, Straus FH, Gill WB: Malignant fi-
brous histiocytoma: An unusual inguinal tu-
mor. J Urol 1972;107:1005–1007.
35 Williamson JC, Johnson JD, Lamm DL, Tio F:
Malignant fibrous histiocytoma of the spermat-
ic cord. J Urol 1980;123:785–788.
36 Tanaka T, Nobuyuki A, Ozaki Y, Matsamura
Y, Ohmori H: Malignant fibrous histiocytoma
originating in the left spermatic cord with a
review of 14 cases in the literature. Jpn J Clin
Oncol 1984;14:437–444.
